Inclisiran sodium is a medication approved for the treatment of people with atherosclerotic cardiovascular disease (ASCVD). ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that binds to PCSK9 messenger RNA, resulting in decreased concentrations of PCSK9 and plasma concentrations of LDL cholesterol.
Chemical Structure:
